Core Insights - Cinda Biopharmaceutical Group has announced a significant global strategic partnership with Takeda Pharmaceutical to accelerate the global development of its next-generation IO and ADC therapies [1] Financial Details - Takeda will make an upfront payment of $1.2 billion to Cinda, which includes a strategic equity investment of $100 million [1] - The subscription price per share is set at HKD 112.56, representing a 20% premium over Cinda's weighted average share price over the past 30 trading days [1] - Cinda is also entitled to receive milestone payments totaling approximately $10.2 billion related to the development and sales of IBI363, IBI343, and IBI3001 (if Takeda exercises its option) [1] - The total potential value of this collaboration could reach up to $11.4 billion [1] Revenue Sharing - Cinda will receive a potential revenue share for each candidate drug outside of Greater China, except for IBI363, which will adopt a profit-sharing model in the U.S. market [1]
信达生物与武田制药达成114亿美元战略合作